Amgen | AMGN

Stock Price
421.51
Daily Change
-2.13 -0.50%
Monthly
-1.95%
Yearly
41.21%
Q4 Forecast
405.65

EPS Reference Time Actual Consensus Previous
2026-11-03 FY2026Q3 PM 5.76 5.64
2026-08-04 FY2026Q2 PM 6.29 5.59 6.02
2026-04-30 FY2026Q1 PM 5.15 4.79 4.90
2026-02-03 FY2025Q4 PM 5.29 4.72 5.31
2025-11-04 FY2025Q3 PM 5.64 5.07 5.58



Peers Price Chg Day Year Date
Takeda 5,731.00 -49.00 -0.85% 33.37% Oct/01
AbbVie 261.59 -1.70 -0.65% 7.04% Sep/30
Agios Pharmaceuticals 33.25 -0.05 -0.15% -17.02% Sep/30
ALKERMES 40.52 -0.28 -0.69% 32.20% Sep/30
Amgen 421.51 -2.13 -0.50% 41.21% Sep/30
Biogen 225.88 -1.19 -0.52% 46.47% Sep/30
BioMarin Pharmaceutical 60.00 0.13 0.22% 9.37% Sep/30
Bristol-Myers Squibb 62.40 -0.46 -0.73% 31.56% Sep/30
Coherus Biosciences 1.21 0.03 2.54% -25.31% Sep/30
Exelixis 58.41 -0.24 -0.41% 41.77% Sep/30

Indexes Price Day Year Date
US500 7671 -19.30 -0.25% 14.23% Oct/01
USND 26861 63.52 0.24% 18.04% Sep/30
US30 51025 -443.87 -0.86% 9.69% Oct/01
US100 30529 69.17 0.23% 22.64% Oct/01

Amgen traded at $421.51 this Wednesday September 30th, decreasing $2.13 or 0.50 percent since the previous trading session. Looking back, over the last four weeks, Amgen lost 1.95 percent. Over the last 12 months, its price rose by 41.21 percent. Looking ahead, we forecast Amgen to be priced at 405.65 by the end of this quarter and at 379.93 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.



News Stream
Amgen Stock Price Hits 4-week Low
Amgen shares decreased to 407.08 USD, the lowest since August 2026. Over the past 4 weeks, Amgen gained 0.05%, and in the last 12 months, it increased 43.85%.
2026-09-08
Amgen Stock Price Hits 11-week High
Amgen shares increased to 358.73 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.78%, and in the last 12 months, it increased 28.52%.
2026-06-25
Amgen Stock Price Hits 5-week High
Amgen shares increased to 345.87 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.8%, and in the last 12 months, it increased 20.51%.
2026-06-04